To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients

Inclusion Criteria: * Diagnosis of UC confirmed by colonoscopy and histology. * Confirmed active UC upon hospital admission, defined by a partial Mayo Score of ≥ 3 with a stool frequency subscore of ≥ 2. * Concomitant therapy for UC will be permitted. Subjects will be instructed not to make any medication changes after hospital discharge before first discussing with the Investigator. * Eligible subjects will be assigned to one of two different and independent patient groups based on C. difficile status as determined by clinical symptoms with diarrhea and laboratory tests: either a polymerase chain reaction (PCR) assay or glutamate dehydrogenase (GDH) screening test used in two- or three-step algorithm with subsequent toxin A and B EIA testing. Exclusion Criteria: * Subjects with history of constipation within a week of the screening visit; or any serious hepatic, renal, cardiovascular, neurological or hematological disorder in the opinion of the Investigator. * Subjects with history of drug or alcohol abuse, history of psychiatric disorders, known allergy or hypersensitivity to beef or any component of SBI. * Subjects with a history of antibiotic treatment within the 4 weeks prior to enrollment. * Subjects using anti-diarrheal medications (e.g., loperamide and bismuth subsalicylate). * Note: anti-diarrheal medications will be prohibited throughout the study. * Subjects who have been admitted to the hospital more than 48 hours prior to enrollment. * Women who are pregnan…